 NORTHBROOK, Ill. and NORTH ADELAIDE, South Australia, May 25, 2021 PRNewswire -- Clarus Therapeutics Inc. Clarus, a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, and HavaH Therapeutics HavaH, an Australia-based biopharmaceutical company developing androgen therapies for inflammatory breast disease and certain forms of breast cancer by using the innate breast-tissue-specific hormoneimmune interface, today announced a licensing agreement whereby Clarus will acquire the exclusive worldwide excluding Australia development and commercialization rights for HAVAH TAiTM CLAR-121. 